ESTRO meets Asia 2024 - Abstract Book

S294

Interdisciplinary – Urology

ESTRO meets Asia 2024

performance time frame to overcome the unstable and unreliable problems for bladder cancer radiotherapy techniques.

Keywords: bladder cancer, adaptive radiotherapy

References:

1. A restrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer, Janice Yeh, Mathias ressel,Keen Hun Tai, Tomas Kron, Fashad Foroudi, Clinical and Translational Radiation Onvology, 30(2021)65-70

2. Image guided adaptive radiotherapy for bladder cancer,V.Kong,V.N.Hansen,S.Hafeez, Clinical Oncology, 30Mach 2021

3.CT-Guided Adaptive Radiotherapy (CT-ART) improves Target Coverage in Hypofracionated radiation therapy for bladder caner,H.B.Stowe, A.Price etc. International Journal of Radiation Oncology, Biology,Physics,2021 ASTRO

4. Adaptive radiation therapy for bladder cancer: a review of adaptive techniques used in clinical practice,Awet Z.Kibrom etc.Journal of Mdical Radiation Sciences 62(2015)277-285

5. Online adaptive radiotherapy compared to plan selecton for rectal cancer: quantifying the benefit, R, de Jong,K.F.Crama etc, Radiation Oncology (2020) Https://dol.org/10.1186/s13014-020-01597-1

365

Proffered Paper

The use of androgen deprivation therapy and radiotherapy for prostate cancer: findings from PCOR-ANZ

Wee Loon Ong 1 , Michelle Steeper 1 , Jonathan Bensley 2 , Krupa Krishnaprasad 1 , Maggie Johnson 1 , Nik Zeps 1 , Jeremy Millar 1 1 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. 2 School of Public Health and Preventive Medicine, Monash University, Melbourn, Australia

Purpose/Objective:

Multiple randomised trials and meta-analyses have shown the oncological benefits of combining androgen deprivation therapy (ADT) and radiation therapy (RT) for prostate cancer. In this study, we aim to evaluate the use of ADT with RT at a population-based level in Australia and New Zealand, and identify any variations in practice.

Material/Methods:

This study included men enrolled in the population-based Prostate Cancer Outcomes Registry Australia and New Zealand (PCOR-ANZ) who were diagnosed with intermediate-risk prostate cancer (IRPC) or high-risk prostate cancer (HRPC) between January 2015 and December 2022, and documented to have RT as the primary treatment. The primary outcome of interest is the use of ADT with RT (yes/ no binary outcomes). Covariables evaluated were